Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Basia Galinski"'
Autor:
Joanna Krzyspiak, Jingqi Yan, Hiyaa S. Ghosh, Basia Galinski, Pablo J. Lituma, Karina Alvina, Alexandra Quezada, Samantha Kee, Marta Grońska-Pęski, Yi De Tai, Kelsey McDermott, J. Tiago Gonçalves, R. Suzanne Zukin, Daniel A. Weiser, Pablo E. Castillo, Kamran Khodakhah, Jean M. Hébert
Publikováno v:
Stem Cell Research, Vol 60, Iss , Pp 102700- (2022)
Externí odkaz:
https://doaj.org/article/68a515075124457184aa08612322ab77
Autor:
Joanna Krzyspiak, Jingqi Yan, Hiyaa S. Ghosh, Basia Galinski, Pablo J. Lituma, Karina Alvina, Alexandra Quezada, Samantha Kee, Marta Grońska-Pęski, Yi De Tai, Kelsey McDermott, J. Tiago Gonçalves, R. Suzanne Zukin, Daniel A. Weiser, Pablo E. Castillo, Kamran Khodakhah, Jean M. Hébert
Publikováno v:
Stem Cell Research, Vol 59, Iss , Pp 102642- (2022)
Neural precursor cells (NPCs) transplanted into the adult neocortex generate neurons that synaptically integrate with host neurons, supporting the possibility of achieving functional tissue repair. However, poor survival and functional neuronal recov
Externí odkaz:
https://doaj.org/article/e8b40cf4b82b434db9390a7e7aa82458
Autor:
Basia Galinski, Marcus Luxemburg, Yosef Landesman, Bruce Pawel, Katherine J. Johnson, Stephen R. Master, Kevin W. Freeman, David M. Loeb, Jean M. Hébert, Daniel A. Weiser
Publikováno v:
Translational Oncology, Vol 14, Iss 8, Pp 101114- (2021)
Across many cancer types in adults, upregulation of the nuclear-to-cytoplasmic transport protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an FDA-approved XPO1 inhibitor. Similar data are emerging in childhood ca
Externí odkaz:
https://doaj.org/article/df22e3a1000a4cbeba345adf608973b1
Autor:
Basia Galinski, Thomas B. Alexander, Daniel A. Mitchell, Hannah V. Chatwin, Chidiebere Awah, Adam L. Green, Daniel A. Weiser
Publikováno v:
Cancers, Vol 13, Iss 6161, p 6161 (2021)
Cancers
Cancers
Simple Summary Exportin-1 is a nuclear transport protein that is overexpressed in cancer cells and associated with inferior outcomes across a range of malignancies. Selinexor is a novel FDA-approved inhibitor of Exportin-1 (XPO1). Although significan
Autor:
Kee S, Yan J, McDermott K, Zukin Rs, Karina Alviña, Grońska-Pęski M, Pablo E. Castillo, De Tai Y, Kamran Khodakhah, Daniel A. Weiser, Krzyspiak J, Pablo J. Lituma, Basia Galinski, Hiyaa S. Ghosh, Jean M. Hébert
SummaryNeural precursor cells (NPCs) transplanted into the adult neocortex generate neurons that synaptically integrate with host neurons, supporting the possibility of achieving functional tissue repair. However, poor survival of transplanted NPCs g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26c198614c7950ff31dae8b7ec315a1e
https://doi.org/10.1101/2021.02.27.433204
https://doi.org/10.1101/2021.02.27.433204
Publikováno v:
Cancer Research. 81:3040-3040
Background: In many adult cancers, upregulation of the nuclear-to-cytoplasmic transport protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an FDA-approved XPO1 inhibitor. Similar data are emerging in childhood can
Publikováno v:
Cancer Research. 78:3193-3193
Background: Neuroblastoma is an embryonic tumor of the peripheral nervous system. Comparative proteomics of high-risk neuroblastoma patients with poor prognosis outcomes demonstrated increased expression of Exportin-1 (XPO1), a nuclear transport prot
Publikováno v:
Cancer Research. 77:1938-1938
Background: Half of patients with high-risk neuroblastoma succumb to disease, yet these patients with inferior outcome cannot be identified at diagnosis despite contemporary risk stratification that integrates MYCN copy number status, tumor histology
Autor:
Basia Galinski, Daniel A. Weiser, Yosef Landesman, Edward F. Attiyeh, David Tauber, Raquel Castellanos
Publikováno v:
Cancer Research. 76:2481-2481
Background: Neuroblastoma (NB) is the most common extracranial solid tumor of childhood and accounts for a disproportionately high fraction (12%) of childhood cancer deaths. More than half of patients with high-risk NB will not survive their disease
Autor:
Basia Galinski, Francis Johnson, Daniel A. Weiser, David Tauber, Lorne M. Golub, Joseph Scaduto, Raquel Castellanos
Publikováno v:
Cancer Research. 76:2481A-2481A
Introduction The chemically modified curcumin, CMC 2.24 (TRB-N0224, Traverse Biosciences Inc.), was designed to overcome the poor solubility, bioavailability, and biological potency of naturally occurring curcumin in an effort to achieve superior saf